Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Opportunistic infections during ibrutinib treatment for B-cell malignancies

Kerry Rogers • 19 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Kerry Rogers, MD, from the Ohio State University, Columbus, OH, discusses the risk of opportunistic infections during ibrutinib treatment for B-cell malignancies, including chronic lymphocytic leukemia (CLL). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Kerry Rogers

2:20
The effect of ibrutinib dose-reduction on outcomes of patients with CLL/SLL: real-world evidence
Kerry Rogers • 8 Dec 2023
4:07
The long-term impact of early lenalidomide treatment on infections and secondary neoplasms in CLL
Kerry Rogers • 8 Dec 2023
5:34
Venetoclax added to ibrutinib in patients with CLL with molecular resistance to BTKi treatment
Kerry Rogers • 8 Dec 2023
1:18
Comorbidity and geriatric assessment tools in routine practice for CLL patients
Kerry Rogers • 7 Oct 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals